blood brain barrier | Medical XPRT
Articles & Whitepapers
-
Intracranial Neoplasms: The Evolution of Radiotherapies
CURRENT STANDARD OF CARE FOR BRAIN TUMORS The current initial standard of care for aggressive brain tumors—whether they are primary brain tumors (ie, tumors that originate in the brain), or metastatic tumors from cancers that started outside of the brain—is resection. After surgery, a follow-up treatment, also referred to as adjuvant treatment, is often recommended to help eliminate ...
-
Nuclear factor I-A regulates diverse reactive astrocyte responses after CNS injury
Abstract Reactive astrocytes are associated with every form of neurological injury. Despite their ubiquity, the molecular mechanisms controlling their production and diverse functions remain poorly ...
News
-
Bayer expands global clinical program for darolutamide in prostate cancer
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET CT at baseline Fifth major ...
Nubeqa (darolutamide) approved for additional prostate cancer indication in China
Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer
Nubeqa approved for additional indication in Japan
New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer
Equipment & Solutions
-
Showcase
Brain-Chip
Research mechanisms of neuroinflammation and evaluate the effect of therapeutics in a comprehensive model of the neurovascular unit